hsa-mir-572: Hsa-mir-572 is a microRNA molecule that has not been previously reported in rats [PMC4334516]. The serum levels of hsa-miR-193a-3p and hsa-miR-362 were found to be significantly increased in patients with renal cell carcinoma (RCC) [PMC6176358]. In patients with IgA nephropathy (IgAN) grade III, the levels of hsa-mir-572 were high compared to control groups [PMC4458130]. However, hsa-mir-572 was not identified as one of the microRNA molecules present in module #451 in a case study on multiple sclerosis [PMC9618768].

MIR572: MIR572 is a microRNA that has been studied in various contexts. In a study conducted in 2014, MIR572 was found to be associated with poor patient survival, suggesting a poor prognosis [PMC6368411]. In another study, MIR572 was among the miRNAs specifically involved in pregnancy and not included in the array [PMC7077927]. Additionally, DMCs associated with MIR572 were found to be related to type 2 diabetes (T2D) [PMC9763387]. Furthermore, MIR572 was identified as one of the miRNAs with good predictive power for distinguishing individuals with autism spectrum disorder (ASD) [PMC6651166]. Specifically, MIR572 was downregulated in individuals with ASD and showed high values for sensitivity, specificity, and area under the curve [PMC6651166]. Overall, these findings suggest that MIR572 may play a role in disease prognosis and diagnosis. However, further research is needed to fully understand its mechanisms and potential therapeutic implications.